Related Experiment Video

Updated: Mar 2, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K

[AT1 blockers - comparability with ACE inhibitors]

Václav Monhart

    Vnitrni Lekarstvi
    |May 19, 2017
    PubMed

    Insights

    Angiotensin II receptor blockers (AT1 blockers) offer comparable cardioprotection to ACE inhibitors, reducing mortality and myocardial infarction. AT1 blockers also show fewer adverse events leading to treatment withdrawal.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Hypertension Management

    Background:

    • The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in cardiovascular regulation.
    • Angiotensin II receptor blockers (AT1 blockers) and ACE inhibitors are key modulators of the RAAS.
    • Understanding their comparative efficacy and safety is vital for clinical practice.

    Purpose of the Study:

    • To compare the effectiveness of AT1 blockers versus ACE inhibitors in reducing mortality and myocardial infarction.
    • To assess the safety profile, specifically treatment withdrawal due to adverse reactions.

    Main Methods:

    • Comparative analysis of patient outcomes in trials involving AT1 blockers and ACE inhibitors.
    • Evaluation of adverse event data leading to discontinuation of therapy.

    Main Results:

    • AT1 blockers demonstrated comparable reductions in overall mortality and cardiovascular mortality versus ACE inhibitors.
    • The incidence of myocardial infarction was similar between the two treatment groups.
    • A significantly lower proportion of patients discontinued AT1 blockers due to adverse reactions compared to ACE inhibitors.

    Conclusions:

    • AT1 blockers provide significant cardioprotection comparable to ACE inhibitors.
    • AT1 blockers offer a favorable safety profile with a lower incidence of treatment discontinuation due to adverse events.

    More Related Videos

    Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice08:15

    Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

    Published on: September 17, 2015

    20.1K
    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

    Published on: October 26, 2020

    5.7K

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    2.9K
    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    2.7K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.3K
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    1.7K
    Antihypertensive Drugs: Action of β1 Blockers01:17

    Antihypertensive Drugs: Action of β1 Blockers

    β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
    2.2K
    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

    β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
    1.6K